Intestinal Transplantation Overview

Principles

Definition

Intestinal transplantation is a specialized area within transplant medicine and surgery focused on the surgical replacement of a diseased or absent small intestine, often combined with other abdominal organs. As a research concept, it encompasses the investigation of complex immunological challenges including rejection and graft-versus-host disease, the development and optimization of surgical techniques and immunosuppressive regimens, and the study of long-term patient and graft outcomes for individuals with irreversible intestinal failure.

Ontological type

Long-term Outcomes

Immunosuppressive Regimens

Indications and Contraindications

Key developments

Key Figures

Foundational Immunobiology era

R. Y. Calne[1], a pioneering figure in immunobiology during the Foundational Immunobiology era, was affiliated with the University of Cambridge[2] and University College London[3] during this period. His 1971 study, GASTROINTESTINAL COMPLICATIONS AFTER RENAL TRANSPLANTATION[4], contributed to the early immunologic characterization of grafts by highlighting mucosal vulnerability and mucosal injury as measurable readouts of immune responses, which helped define time-course markers and shaped perioperative prophylaxis and therapeutic strategies. This body of work by Calne[1] helped establish immunologic signatures of rejection and mucosal vulnerability that informed subsequent immunosuppressive approaches in intestinal transplantation. Overall, Calne[1]'s contributions in this era provided foundational insights into histopathology and graft–host interactions that guided early clinical practice and experimental models.

Integrated Multivisceral Transplantation era

Thomas E. Starzl[1] is a pioneering figure in integrated multivisceral transplantation with affiliations at Rockefeller University[3] and the University of California, San Francisco[4] during this era. His contributions in this era include detailing biliary tract complications in human orthotopic liver transplantation[7], reporting on transplantation of multiple abdominal viscera[9], and outlining the evolving status of intestinal transplantation in children[8], which collectively helped turn experimental concepts into reproducible, life-saving therapies. Satoru Todo[2] is associated with The University of Texas Health Science Center at San Antonio[5] and the University of Minnesota[6] in this era. Todo's key contributions, reflected in the same papers—biliary tract complications in orthotopic liver transplantation[7] and the current status of intestinal transplantation in children[8]—aided clinical understanding and standardization of care for complex abdominal transplants in pediatric patients, catalyzing program growth and broader access during the integrated multivisceral era.

Microbiome-Driven Optimization era

Zain Kassam [1] is a leading figure in intestinal transplantation research during the Microbiome-Driven Optimization era (2015–2022), with affiliations at Harvard University [3] and the Massachusetts Institute of Technology [4]. His contributions include the randomized controlled trial Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial [7], the report Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach [8], and the donor eligibility assessment described in Prospective Assessment of Donor Eligibility for Fecal Microbiota Transplantation at a Public Stool Bank: Results From the Evaluation of 1387 Candidate Donors [9], collectively advancing microbiome-based therapies and donor screening as central to post-transplant care in this era. Michael G. Surette [2], affiliated with McMaster University [5] and the University of Calgary [6] during this era, has contributed to the same line of inquiry. His notable contribution in this era is as a co-author of the 2015 Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial [7], illustrating how microbiome-driven therapies can reshape post-transplant care and reduce infection-related morbidity.